Donald Lloyd-Jones, MD

Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Dr. Lloyd-Jones’ research interests include the study of the mechanisms and life course of cardiovascular health and healthy aging, and cardiovascular disease epidemiology, risk estimation and prevention. Other areas of interest include the use of novel biomarkers and imaging of subclinical atherosclerosis to improve prevention, and the epidemiology and outcomes of hypertension and dyslipidemia. His clinical and teaching interests lie in general cardiology, with a focus on prevention.

He also has been a national leader in public health and clinical approaches to promoting cardiovascular health and preventing cardiovascular diseases across the life course. He served as co-chair of the Risk Assessment Guidelines and a member of the Cholesterol Treatment Guidelines Panel for the 2013 ACC/AHA Guidelines for Cardiovascular Disease Risk Reduction; and was the lead member for risk assessment on the 2018 Cholesterol Guidelines Panel and the 2019 Primary Prevention Guidelines Panel. He has authored over 750 peer-reviewed scientific publications and has been a PI or co-investigator on more than 120 grants (the vast majority from NIH)

Publications

  • Published 7/1/2026

    Bhatt SP, Sun Y, Wang Y, Balte PP, Schwartz JE, Cassano P, Chaves PH, Couper D, Jacobs DR, Kalhan R, Kaplan RC, Lloyd-Jones D, Newman AB, O'Connor GT, Sadatsafavi M, Umans JG, White WB, Yende S, Oelsner EC. Life Expectancy in Chronic Obstructive Pulmonary Disease. JAMA Intern Med. 2026 Jul 01; 186(7):852-860. PMID: 42143630.

    Read at: PubMed

  • Published 6/9/2026

    Khan SS, Bhave N, Blumenthal RS, Coresh J, Huang X, Joseph JJ, Khera A, Ho JE, Lloyd-Jones DM, Low Wang CC, Lu Y, Morris PB, Nasir K, Natarajan P, Rangaswami J, Rodriguez F, Sperling LS, Virani SS, Zhang S, Ndumele CE. Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation. 2026 Jun 09. PMID: 42263147.

    Read at: PubMed

  • Published 6/9/2026

    Khan SS, Ndumele CE, Bhave N, Blumenthal RS, Coresh J, Huang X, Joseph JJ, Khera A, Ho JE, Lloyd-Jones DM, Low Wang CC, Lu Y, Morris PB, Nasir K, Natarajan P, Rangaswami J, Rodriguez F, Sperling LS, Virani SS, Zhang S. Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2026 Jun 09. PMID: 42263012.

    Read at: PubMed

  • Published 6/1/2026

    Khan SS, Huang X, Coresh J, Shah NS, Lloyd-Jones DM, Echouffo-Tcheugui JB, Matsushita K, Ndumele CE. Racial and Ethnic Differences in Predicted Cardiovascular Disease Risk Using the PREVENT Equations in the US Population. Circ Popul Health Outcomes. 2026 Jun 01; e012102. PMID: 42220236.

    Read at: PubMed

  • Published 6/1/2026

    Khan SS, Ndumele CE, Lloyd-Jones DM. Statin Eligibility According to Atherosclerotic Cardiovascular Disease Risk in the US-Reply. JAMA Cardiol. 2026 Jun 01; 11(6):610-611. PMID: 41920527.

    Read at: PubMed

View All 870 Publications:   View Full Profile in BUMC

Other Positions

  • Director of Framingham Center for Population and Prevention Science, Framingham Heart Study
    Boston University
  • Principal Investigator of the Framingham Heart Study, Framingham Heart Study
    Boston University
  • Chief of the section, Preventive Medicine
    Boston University

Websites

Education

  • Columbia University College of Physicians and Surgeons, MD
  • Harvard School of Public Health, MS
  • Swarthmore College, BA

View all profiles